Navigation Links
Sosei Announces Outcome of Strategy Review

TOKYO, May 14 /PRNewswire-FirstCall/ -- Sosei Group Corporation ("Sosei"; TSE Mothers Index: 4565), a biopharmaceutical company, today announces the outcome of its strategy review.

In view of the current market conditions, the difficulty in raising finance at the current low share price, and the problems associated with the AD923 device which has necessitated a halt to the Phase III trials Sosei has taken decisive action to cut costs, streamline its operation and to secure the future of the business until it becomes a significant income generating business from NVA237/QVA149 in a few years time.

- Sosei is closing its Chesterford operation and Sosei R&D's

continuing business will relocate to London in due course. This will

reduce UK headcount by c 40 staff and provide a full years cost saving of

around $4M.

- Sosei will no longer operate a drug discovery unit.

- Sosei R&D will maintain the rights to NVA237/QVA149 but seek

to out-license or sell all other assets generated in the UK including

AD923 and its discovery assets whilst seeking to retain some rights for

the Asian market.

- Tokyo will continue to develop Norlevo and explore other

in-licensing opportunities.

This restructuring and portfolio review will provide Sosei with at least two years cash based on the post-restructuring cash burn including a budget allocation to explore some late stage product opportunities for future expansion but without the inclusion of any income from licensing or sales deals for its compounds.

Notes for Editors:

About Sosei

Sosei Group Corporation is a leading international biopharmaceutical company with significant expertise in product discovery and development. It has established a reduced risk business model primarily upon identifying new uses for established drugs and exploiting its unique position within Japanese, European and North American pharmaceutical mark

SOURCE Sosei Group Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Sosei Announces Completion of Phase II Trial of AD 337 in Fibromyalgia Syndrome
2. BD Announces Acquisition of Cytopeia
3. Chindex International Announces Shelf Registration, Related Strategy and Guidance
4. Amicus Therapeutics Announces First Quarter 2008 Financial Results
5. Chindex International Announces Conference Call to Discuss Its Fiscal 2008 Fourth Quarter and Year End Results on Thursday, June 12, 2008
6. Jazz Pharmaceuticals, Inc. Announces First Quarter 2008 Financial Results
7. China Sky One Medical, Inc. Announces Record First Quarter 2008 Results
8. Synvista Therapeutics Announces Initiation of the BREAK Study of Alagebrium for Diastolic Heart Failure
9. Palatin Technologies Announces New Strategic Objectives and Reports Third Quarter 2008 Financial Results
10. SGX Pharmaceuticals Announces First Quarter Financial Results and Gives Pipeline Update
11. Aton Pharma Announces Distribution Partnership in Brazil
Post Your Comments:
(Date:6/26/2015)... Ottawa, ON (PRWEB) , ... June 26, 2015 ... ... kits and end-to-end services and a subsidiary of OraSure Technologies, Inc. (Nasdaq: OSUR) ... innovative microbiome research, as part of its Gut Microbiome Grant Program. The company ...
(Date:6/25/2015)... , June 25, 2015 Last June, a ... to track the virus using large-scale genome sequencing. Their research, ... June 18 in the journal Cell (Park ... and mutated over seven months of the recent Ebola outbreak. ... working draft, data, workflows, and full edit history of ...
(Date:6/25/2015)... (PRWEB) , ... June 25, 2015 , ... ... of keynotes speakers for its 2015 National Patient and Family Conference, Providing and ... in Chicago at the Renaissance Chicago O’Hare Suites Hotel, July 24-25, 2015. , ...
(Date:6/25/2015)... , June 25, 2015  The Galien Awards ... of Genome Sciences and Medical Genetics at the University ... Pro Bono Humanum Award at the ninth annual Prix ...   The Pro Bono Humanum Award ... is the first woman recipient of the award.   ...
Breaking Biology Technology:DNA Genotek Inc. Announces Recipients of Gut Microbiome Grant Program 2DNA Genotek Inc. Announces Recipients of Gut Microbiome Grant Program 3Open Science Takes Major Leap Forward 2Nationally Recognized Brain Tumor Experts to Speak at American Brain Tumor Association Patient and Family Conference 2The Prix Galien USA Awards Committee Selects Professor Mary-Claire King as 2015 Pro Bono Humanum Honoree 2The Prix Galien USA Awards Committee Selects Professor Mary-Claire King as 2015 Pro Bono Humanum Honoree 3
... students Steven T. Evans, Tobias Voitl, Gabriel R. Rodriguez-Rivera, ... MADISON - Carbon monoxide, or CO, has long been ... fuel cells. But now, chemical and biological engineers at ... barrier - they also have discovered a method to ...
... have mercy, otherwise, our produce will not be discovered and ... day. The festivities are full steam ahead, the skateboarding mathematicians ... sticks while sipping champagne, and they are now calculating the ... ,Looking from a wider angle, it seems that the big ...
... Thursday with Capital Data, Inc. , an ... services, according to TeraMEDICA's executive vice president, Paul ... bundle TeraMEDICA's TI2m archive solution into its own ... that includes Wisconsin, Minnesota, North Dakota, South Dakota, ...
Cached Biology Technology:UW engineers clear bottleneck in hydrogen production 2Lord of the Engines 2Lord of the Engines 3TeraMEDICA and Capital Data enter into diagnostic imaging agreement 2
(Date:6/26/2015)... -- ATL Technology, LLC, a top provider of electromechanical contract ... solutions, headquartered in Springville, Utah , has ... corporation with locations in Santa Clara, ... ). This acquisition will incorporate MedConx,s manufacturing ... Technology,s existing facility in Costa Rica , ...
(Date:6/25/2015)... N.J. , June 25, 2015  TAKE Solutions ... a patent by the United States Patent and Trademark ... Standardization". This process leverages TAKE Solutions, Clinical Accelerators to ... over 50% (when compared to standardization without the accelerators), ... At the heart of ...
(Date:6/24/2015)... JOSE, Calif. , June 24, 2015 /PRNewswire/ ... developer of human interface solutions, today announced that ... sensor to provide secure authentication for its latest ... recently reached more than 200 million shipments of ... with Sharp reinforces Synaptics, strength, scalability and leadership ...
Breaking Biology News(10 mins):ATL Technology Announces Acquisition of MedConx, Inc. and Expanded Global Footprint 2TAKE Solutions Awarded Patent By USPTO 2Synaptics Brings Natural ID Technology to Sharp's Newest Flagship Smartphone 2
... exposed to low doses of atrazine, a widely used herbicide, ... through puberty later than non-exposed animals. The research adds to ... used to control weeds and grasses in crops such as ... to be relatively persistent in the environment, potentially finding their ...
... current issue of Deutsches rzteblatt International (Dtsch ... pharmacologist, and coauthors present the PRISCUS List: a list ... effects when given to elderly patients. The authors ... Germany in the setting of a joint project entitled ...
... Chinese on EurekAlert! Chinese . ... Medicine, Hershey, Pennsylvania have discovered that the Opioid Growth ... important system with potent antitumor properties, has controlled entry ... passage of OGF-OGFr is critical to cell proliferation and ...
Cached Biology News:Atrazine causes prostate inflammation in male rats and delays puberty 2Regulation of cell proliferation is dependent on nucleocytoplasmic trafficking 2Regulation of cell proliferation is dependent on nucleocytoplasmic trafficking 3
... Serum • Cyno serum is collected off the clot ... years of age. Available Anticoagulants: ... N-06: K2EDTA N-08: Potassium Oxalate ... N-05: ACD N-07: CPD N-09: ...
Marmoset plasma and serum - various quantities available...
DNA Purification...
EPH electrode, cathode, 1. Category: Electrophoresis Systems & Standards & Reagents, IEF & SDS-PAGE & 2-D Electrophoresis, Multiphor II Kits & Components and Accessories....
Biology Products: